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Background: Numerous clinical trials have contributed to rapid advancements in the diagnosis and
management of pulmonary arterial hypertension (PAH), yet patients often do not undergo right heart
catheterization (RHC) with vasoreactivity testing and may receive a delayed or incorrect diagnosis. Ef-
forts to improve standards of care include the designation of Pulmonary Hypertension Association
(PHA)-Accredited PH Care Centers (PHCCs). This study evaluated current practices in the diagnosis and
assessment of PAH.
Methods: A survey of 167 physicians who had 1 claim for PAH in the past 3 months was conducted.
Results: Of 167 respondents, 15% were afﬁliated with a PHCC, 40% had referred 1 patient with diag-
nosed PAH, and 79% had 1 patient referred to them by another physician who they then newly diag-
nosed with PAH. More than half (52%) reported having 1 patient who was previously misdiagnosed
with PAH referred to them by another physician. RHC and vasoreactivity testing, respectively, were
performed in 43% and 33% of patients with PAH who respondents referred to another physician, 86% and
67% of patients newly diagnosed by respondents, and 84% and 57% of patients who respondents
considered accurately diagnosed prior to being referred to them. Respondents afﬁliated with a PHCC
were more likely to try to refer to another physician afﬁliated with a PHCC, and to perform RHC and
vasoreactivity testing.
Conclusions: Self-reported clinical practices often deviated from established guidelines. Future research
should focus on both clinical efﬁcacy and ways to encourage clinicians to bring their practices in line with
well-supported, evidence-based recommendations.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Data from a multitude of clinical trials have contributed to rapid
advancements in the management of pulmonary arterial hyper-
tension (PAH) [1e5], and PAH is the focus of many ongoing trials
[6e11]. However, the beneﬁts of these advances for patients can be
limited by the capacity of physicians to adopt practices supported
by evidence from well-designed studies.
PAH is a rare type of pulmonary hypertension (PH) and isunctional classiﬁcation; PAH,
e physicians; PH, pulmonary
tion; PHCCs, Pulmonary Hy-
tion; SHS, Symphony Health
com (S. Polanco-Briceno),
(A. Caze).
Inc. This is an open access article uspeciﬁcally deﬁned as increased pulmonary vascular resistance that
can ultimately lead to right ventricular failure and death
[2e4,12,13]. Four classes of functional status have been deﬁned by
the World Health Organization. Patients with Functional Classiﬁ-
cation (FC) Class I PH are the least affectedwhereas thosewith Class
IV PH are signiﬁcantly functionally impacted [14,15].
PAH is deﬁned by hemodynamic measures, including a mean
pulmonary artery pressure >25 mm Hg at rest or >30 mm Hg with
exercise [2,15]. Right heart catheterization (RHC) is the diagnostic
gold standard for PAH, in part because echocardiography can only
provide an estimate of pulmonary artery pressure [2,13,15,16].
Accurate diagnosis of PAH and exclusion of other types of PH is
crucial to optimal management [14]. PAH-speciﬁc therapies have
not been shown to beneﬁt patients with other forms of PH, and
inappropriate treatment can prevent or delay the introduction of
more beneﬁcial treatment and/or directly harm the patient [13,14].
Ideally, vasoreactivity testing is done during RHC to determine
whether the patient might beneﬁt from treatment with a calciumnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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adequate level of vasoreactivity are unlikely to beneﬁt from CCB
therapy yet would still be at risk for treatment side effects [15].
Although only a small subset of patients with PAHwill demonstrate
vasoreactivity sufﬁcient to justify CCB treatment, short-term vas-
oreactivity testing is currently the only method of identifying those
patients [2,15].
Advancements in the diagnosis and management of PAH have
produced novel treatments and improved patient outcomes, and
could have an even greater positive impact on healthcare [2,4,17].
However, in many cases evidence-based recommendations such as
published guidelines are not followed [12,14,17e19]. A substantial
delay between symptom onset and diagnosis still occurs in many
patients, with the majority of patients diagnosed when they are
already in FC Class III or IV, despite better outcomes being associ-
ated with FC Classes I and II [4,17,19]. Other issues include misdi-
agnosis and inappropriate therapy [19]. To improve standards of
care, the Pulmonary Hypertension Association (PHA) has devel-
oped a program for accreditation of centers demonstrating exper-
tise in PH, with particular emphasis on PAH [17].
The objective of this studywas to evaluate actual practices in the
diagnosis, assessment, and treatment of PAH. The goals were to
understand: which physicians are diagnosing PAH; the methods
used for diagnosis, evaluation, and treatment; how patients with
diagnosed or suspected PAH are referred between physicians; and
at which point in the progression of the disease patients tend to be
diagnosed and/or referred.
2. Methods
2.1. Survey sample design
A universe sample frame of PAH-treating physicians in the US
was created by sourcing 2013 insuranceeclaims activity for PAH
therapies from Symphony Health Solutions (SHS). SHS is a leading
source of nationally representative and comprehensive physician
prescribing information in the US. A total of 2594 physicians who
had at least one insurance claim for PAHwere invited by postal mail
and email to participate in an online study regarding PH. At this
point, physicians voluntarily self-screened based on knowledge,
interest, and experience level in PH. As it is unknown how many
physicians successfully received, reviewed, and self-screened for
this survey invitation, a true response rate cannot be calculated for
this recruitment methodology. However, it is assumed that
participation in this survey was random and represented basic in-
terest and knowledge in this disease area.
In order to qualify for the survey, physicians had to personally
have made treatment decisions and/or adjustments for at least one
patient speciﬁcally to manage PAH in the previous three months.
They also had to be willing to provide accurate responses to
questions about their professional experiences.
2.2. Ethics, consent, and permission
Physicians were offered an industry-standard honorarium for
their time to complete the survey. By opting in to the survey, the
respondents provided consent to use their anonymized responses
to the survey questions. Because this study did not involve patients
or patient data, Institutional Review Board approval and patient
consent were not required.
2.3. Survey and data collection
The survey was live between June 11 and July 12, 2015, and was
comprised of 22 quantitative and eight qualitative questions.Quantitative questions addressed the total volume of patients
treated for PH and PAH, the type of physician who diagnosed/
referred patients, tools used for diagnosing, and functional class at
time of diagnosis. Additional quantitative questions that were un-
related to this analysis include volume of current patients in each
functional class, current therapy (by functional class), and overall
treatment approach by line of therapy; these results will not be
presented here. Qualitative questions included those relating to
how a diagnosis was determined among patients who did not have
an RHC andwhy patients who did not receive vasoreactivity testing
were not tested. Additional questions not included in this analysis
related to the rationale for their treatment approach among FC
Class I and FC Class IV patients, rationale for brand preference (if
any), and rationale for whether they use PAH-speciﬁc medications
to treat patients with PH. The survey also contained a short de-
mographic section that asked respondents to provide their gender,
the number of years in practice, the location and the setting of their
practice, afﬁliation with any academic medical center, and per-
centage of professional time spent in direct patient care vs research
and teaching vs other professional duties (e.g., hospital/practice
administration).
2.4. Data analysis
All survey data were analyzed in the aggregate, and study au-
thors were blinded to the individual identities of physician survey
respondents. Responses to the closed questions were analyzed
quantitatively. Responses to openeended questions were coded
into predetermined categories that were developed based on four
telephone interviews with two pulmonologists and two cardiolo-
gists with current experience treating PAH. A response that
addressed multiple categories was counted as multiple comments.
SPSS Version 20 (IBM Corp. Released 2011. IBM SPSS Statistics for
Windows, Version 20.0. Armonk, NY: IBM Corp.) was used to
perform the appropriate statistical analyses in order to test for
signiﬁcant differences between two subgroups (those afﬁliated
with a PHA-Accredited PHCC and those not afﬁliated with a PHA-
Accredited PHCC), although the sample size for one group (those
afﬁliated with a PHA-Accredited PHCC) was lower than ideal for
this comparison. Two-sided test p-values less than 0.05 were
considered statistically signiﬁcant. Multiple comparisons were not
adjusted.
3. Results
Of the 184 physicians who entered the screener, 136 were pul-
monologists, 33 were cardiologists, 11 were primary care physi-
cians (PCPs), and four were rheumatologists (Table 1). Of the 136
pulmonologists who entered the screener, 129 qualiﬁed and
completed the survey (although one was excluded for data quality
issues), two qualiﬁed but did not complete the survey, and one did
not qualify due to not personally making treatment decisions or
adjustments speciﬁcally to manage PAH in the past three months. A
total of 32 cardiologists completed the screener, 28 qualiﬁed and
completed the rest of the survey, three qualiﬁed but did not com-
plete the rest of the survey, and one did not qualify due to not
personally making treatment decisions or adjustments speciﬁcally
to manage PAH in the past three months. Out of the 11 PCPs who
entered the screener, eight qualiﬁed and completed the survey, one
qualiﬁed but did not complete the rest of the survey, and two did
not qualify due to not personally making treatment decisions or
adjustments speciﬁcally to manage PAH in the past three months.
Finally, all three of the rheumatologists who completed the
screener qualiﬁed and completed the rest of the survey. An addi-
tional four pulmonologists, one cardiologist, and one
Table 1
Respondent disposition.
Invited 2594
Entered screener 184
Pulmonologists 136
Completed the screener 133
Qualiﬁed and completed the survey (1 later excluded for data quality issues) 129
Qualiﬁed but did not complete the survey 2
Did not qualify 1
Cardiologists 33
Completed the screener 32
Qualiﬁed and completed the survey 28
Qualiﬁed but did not complete the survey 3
Did not qualify 1
Primary care physicians 11
Qualiﬁed and completed the survey 8
Qualiﬁed but did not complete the survey 1
Did not qualify 2
Rheumatologists 4
Completed the screener 3
Qualiﬁed and completed the survey 3
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questions to verify their qualiﬁcation for the survey.
A total of 167 qualiﬁed physicians (physicians who referred or
personally made treatment decisions or adjustments for at least
one patient with PAH in the three months prior to the survey)
provided responses. The majority of qualiﬁed respondents were
male (84%), and the mean number of years in practice was 16.5.
Most (77%) were pulmonologists (Table 2). A small percentage of
respondents were afﬁliated with a PHA-Accredited PHCC (15%,
n ¼ 25). However, most were not afﬁliated with a PHA-Accredited
PHCC (72%, n¼ 120), somewere familiar with this accreditation but
were not sure if their center was accredited (8%, n ¼ 14), and a few
(5%, n ¼ 8) reported being unfamiliar with this type of
accreditation.
Respondents had managed a mean of 31 patients with PAH in
the three months prior to the survey. Ninety-six percent of re-
spondents had diagnosed PAH in a patient and 99% had made
treatment decisions for patients with PAH. Most patients with PAH
seen by respondents were FC Class II (32%) or FC Class III (38%).Table 2
Respondent characteristics.
Specialty
Internal Medicine
Pulmonology
Cardiology
Rheumatology
Number of patients with PAH managed in the last 3 months
Mean
Median
WHO functional classiﬁcation of patients seen
FC Class I
FC Class II
FC Class III
FC Class IV
Respondents who, in the last 3 months:
Diagnosed PAH
Made treatment decisions for PAH
Afﬁliated with a PHA-Accredited PHCC
Yes
No
Familiar with accreditation, but unsure if afﬁliated centers are accredi
Unfamiliar with accreditation
Abbreviations: FC, Functional Classiﬁcation; PAH, pulmonary arterial hyper
Hypertension Care Center; WHO, World Health Organization.3.1. Referral patterns
Referrals among physicians were relatively common; 21% of
respondents had referred at least one patient with suspected PAH
to another physician and 40% had referred at least one patient with
diagnosed PAH (Fig. 1). The majority of respondents (79%) had at
least one patient referred to them by another physician who they
then newly diagnosed with PAH. Although 65% of respondents re-
ported having at least one patient with correctly diagnosed PAH
referred to them by another physician, more than half (52%) re-
ported having at least one patient who was previously mis-
diagnosed with PAH referred to them by another physician. Overall,
an average of 10 patients were either referred to respondents by
another physician for PAH or newly diagnosed with PAH by re-
spondents in the three months prior to the survey. Of those, 31%
had been accurately diagnosed with PAH before referral, 19% were
misdiagnosed with PAH before referral, and 49% were newly
diagnosed with PAH by respondents.
Of patients who were ﬁrst evaluated for and diagnosed with
PAH by respondents, 60% of patients had slightly more severeAll qualiﬁed respondents (N ¼ 167)
5%
77%
17%
2%
31
25
15%
32%
38%
14%
96%
99%
15%
72%
ted 8%
5%
tension; PHA, Pulmonary Hypertension Association; PHCC, Pulmonary
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patients who were ﬁrst diagnosed by respondents after being
referred by another physician were FC Class III or IV. Overall, pa-
tients who were referred out for PAH tended to have slightly more
severe illness, with 71% of patients in FC Class III or IV at the time
they were referred.
As noted earlier, a small proportion of respondents reported that
they were afﬁliated with a PHA-Accredited PHCC (15%, n ¼ 25).
Most respondents reported that they were not afﬁliated with a
PHA-Accredited PHCC (72%, n ¼ 120), and the remaining were
either unsure if sure if their center was accredited or were unfa-
miliar with this type of accreditation. Of those who identiﬁed as
being afﬁliated with a PHA-Accredited PHCC, 92% (23 of 25) re-
ported making an effort to refer patients to a physician who was
also afﬁliated with a PHA-Accredited PHCC, which was signiﬁcantly
greater than the proportion of respondents who identiﬁed as not
being afﬁliated with a PHA-Accredited PHCCwho did likewise (48%,
68 of 142) (p < 0.001).0
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Fig. 2. Disease severity at time of referral, Ab3.2. Diagnostic testing e right heart catheterization
More than half (57%) of patients with PAH who respondents
referred to another physician did not have an RHC (Fig. 3). Most
respondents reported that the diagnosis of PAH among these pa-
tients had been made based on tests such as echocardiogram, often
in combination with clinical symptoms.
A total of 14% of patients who were newly diagnosed with PAH
by respondents, and 16% of patients accurately diagnosed with PAH
by another physician before being referred to respondents, had not
had RHC. A smaller percentage of patients who were newly diag-
nosed with PAH by respondents afﬁliated with a PHA-Accredited
PHCC had not had an RHC (4%) compared with those not afﬁli-
ated with a PHA-Accredited PHCC (17%), although this difference
was not signiﬁcant (p ¼ 0.484). Physicians were asked an open-
eended question regarding why these patients had not undergone
an RHC to conﬁrm the diagnosis of PAH; responses were coded
using predetermined categories. Of respondents who had at least
one patient who had not had an RHC (n ¼ 45), 84% reported thatdent before diagnosis
y respondent)
Not referred - first diagnosed by
respondent
FC Class III FC Class IV
breviation: FC, Functional Classiﬁcation.
0 10 20 30 40 50 60
Overall
Affiliated with PHA-Accredited PHCC
Not affiliated
Percent of respondents
Had newly diagnosed ≥1 patient without RHC
Had received ≥1 referral of a patient without RHC
Had referred ≥1 patient without RHC
Fig. 3. RHC patterns.
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echocardiogram/2-D echo Doppler.3.3. Diagnostic testing e vasoreactivity testing
Respondents reported that a larger proportion of patients newly
diagnosed by them (either whose ﬁrst discussion about PAH was
with them or who were referred by another physician who had not
yet diagnosed them) were tested for vasoreactivity (67%) compared
with those referred to them by another physician who had already
accurately diagnosed them with PAH (57%) (Fig. 4). In addition,
most patients (67%) referred out by respondents had not received
vasoreactivity testing speciﬁcally to determine candidacy for CCBs.
A smaller proportion of patients diagnosed by respondents afﬁli-
ated with a PHA-Accredited PHCC (22%) did not have vasoreactivity
testing compared with those not afﬁliated with a PHA-Accredited
PHCC (28%), although this difference was not signiﬁcant
(p ¼ 0.608). Physicians were asked an openeended question
regarding why these patients had not undergone vasoreactivity
testing and responses were coded using predetermined categories.
Of those respondents who personally diagnosed at least one patient
who had not undergone vasoreactivity testing, 25% reported they
do not routinely test because they do not believe that CCBs are
effective in treating PAH, and 11% felt that testing was unnecessary0 10 20
Overall
Affiliated with PHA-Accredited PHCC
Not affiliated
Fig. 4. Vasoreactivitydue to the low probability of ﬁnding a candidate for CCB treatment
(with a net of 31%mentioning either one of those reasons). The next
most common reason, reported by 25% of physicians, was that the
patient was referred and re-doing the RHC for the vasoreactivity
testing would not be worthwhile. Other reasons included lack of
capability/cardiologist who performed it (mentioned by 16%), pa-
tient contraindications (mentioned by 16%), bypassing the test by
empirically trying CCBs (mentioned by 9%), suspicion of etiology
not supporting candidacy for CCBs (mentioned by 7%), patient
refusal (mentioned by 3%), and cost/insurance issues (mentioned
by 3%).4. Discussion
PAH is a rare condition, particularly compared with the rela-
tively common larger category of PH [2,13,15]. RHC is required to
conﬁrm a PAH diagnosis, with associated vasodilator testing
necessary to evaluate patient suitability for CCB treatment [2,13,15].
Differences in diagnosis and treatment between types of PH make
accurate diagnosis of PAH of paramount importance in effective
patient treatment [14].
Although only a small proportion of patients with PAH will
beneﬁt from CCB therapy, the potential beneﬁt to those patients is
substantial [2,15]. However, due to the rarity of substantial30 40 50 60 70 80
Percent of respondents
Had newly diagnosed ≥1 patient 
without vasoreactivity testing
Had received ≥1 referral of a patient 
without vasoreactivity testing
Had referred ≥1 patient without 
vasoreactivity testing
testing patterns.
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with CCBs in untested patients is very likely to fail, thus delaying
effective treatment [2].
Respondents in this study had managed an average of 31 pa-
tients with PAH in the previous three months, making diagnoses as
well as treatment decisions. Although rates of RHC usage were
relatively high among this experienced group, it was less likely to
be done in patients they had referred to other physicians. Vaso-
reactivity testing was performed in only about one third of patients.
Referrals of patients with suspected or diagnosed PAH were
common, with respondents seemingly more likely to receive re-
ferrals than to refer patients with PAH to other physicians them-
selves. Respondents were not asked to report on any misdiagnoses
of their own that they had been made aware of, but more than half
reported having at least one patient who was previously mis-
diagnosed referred to them by another physician.
In this study, the majority of respondents were pulmonologists
and only 5% were not aware of the existence of PHA-Accredited
PHCCs. The requirements for PHA-Accredited PHCCs include a
cardiac catheterization laboratory as well as an echocardiography
laboratory. Staff at these centers must follow available diagnosis
and treatment consensus guidelines when possible, must have
experience with acute vasodilator testing, and be proﬁcient with
PAH therapies [20]. Respondents afﬁliated with a PHA-Accredited
PHCC were more likely to try to refer to a physician also afﬁliated
with a PHA-Accredited PHCC, as well as to follow established
evidence-based guidelines by performing RHC and vasoreactivity
testing.
The limitations of this study include possible enrollment bias
and the inherent limitations of self-reported data. Cause and effect
cannot be established from these data. For example, where physi-
cian behavior deviated from guideline recommendations, it is not
known whether the physician was unaware of the recommenda-
tions, did not agree with the recommendations, or had patients
who were justiﬁably outside of the scope of the recommendation
(e.g., patients in whom vasoreactivity testing was contraindicated).
In addition, the small sample size of respondents who were afﬁli-
ated with a PHA-Accredited PHCC (n¼ 25,15%) may account for the
lack of statistical signiﬁcance in some of the statistical comparisons.
Despite the many advances made in the management of PAH,
the need for improvements remains. Patients with PAH cannot
beneﬁt from the knowledge gained in clinical studies if clinicians
do not incorporate these ﬁndings into their practices. The results
reported here are in concordance with other reported ﬁndings of
suboptimal PAH management [12,14,17,18], and indicate that future
research should focus not only on clinical efﬁcacy but also on ways
to encourage clinicians to bring their practices in line with well-
supported, evidence-based recommendations. Potential methods
for improving adherence among physicians at the individual level
could include education on current evidence-based recommenda-
tions made easily accessible and possibly including CME activities
to encourage participation. In addition, incentives for physicians
should be based on following best practices. Physicians should also
be made aware of the existence of PHA-Accredited PHCCs and
encouraged to refer patients to such centers. At the institutional
level, efforts should be made to encourage healthcare facilities with
a high volume of patients with PH or PAH tomove towards fulﬁlling
the standards to become a PHA-Accredited PHCC. Finally, reim-
bursement should be designed to reﬂect evidence-supported best
practices.
5. Conclusions
Deviations from established, evidence-based guidelines were
self-reported by a group of physicians selected for experience withPAH and who had substantial involvement in PAH diagnosis and
treatment. Afﬁliation with a PHA-Accredited PHCC was associated
with better practices, indicating that further education and efforts
to change physician behavior are likely to be effective in improving
outcomes for patients with PAH.
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